Overview

Prevention and Treatment for COVID -19 (Severe Acute Respiratory Syndrome Coronavirus 2 SARS-CoV-2) Associated Severe Pneumonia in the Gambia

Status:
Recruiting

Trial end date:
2022-07-01

Target enrollment:

Participant gender:

Summary

The trial aims to assess the impact of cheap, licenced and widely available investigational products on the natural history of SARS-CoV-2 infection in 2 groups of patients - those with mild or moderate pneumonia (Cohort 1) and those with severe pneumonia (Cohort 2), through randomisation to non-identical placebo or intervention arm.

Phase:

Phase 3

Details

Lead Sponsor:

London School of Hygiene and Tropical Medicine

Treatments:

Ivermectin